N/A
Loading page data
Please wait a moment
Search Report
Loading page data
Please wait a moment
Acute myeloid leukemia (AML) is cancer that initiates inside bone marrow and affects the whole blood. Acute myeloid leukemia (AML) is not just a single disease but a group of leukemias that develops in the myeloid cell line in the bone marrow. Acute myeloid leukemia (AML) occurs due to overproduction of immature white blood cells often known as myeloblast or leukemic blast. Cancer develops from cells that would normally turn into white blood cells.
The myeloblast gathers in the bone marrow, preventing it from making normal blood cells. This results in disturbing the growth of other blood cells in the body leading to weaker immunity. The pathophysiology of acute myeloid leukemia (AML) is just beginning to be understood at the molecular level, and currently, biomarkers markers are the most important for risk stratification and treatment of acute myeloid leukemia (AML) patients.
However, with the advent of new advanced technologies, the detection of many molecular markers for acute myeloid leukemia such as point mutations and characterization of epigenetic and proteomic profiles, have begun to play a vital role in how the cancer is approached.
Recent studies show that the identification of new acute myeloid leukemia (AML) biomarkers contributes to a better understanding of the molecular basis of the disease, is significantly helpful in diagnosis, screening, prognosis, and monitoring of acute myeloid leukemia, as well useful for predicting each individual's response to treatment. Common molecular biomarkers for acute myeloid leukemia (AML) includes FLT3-ITD, CEBPA, NPM1, and cKIT.
Rapidly growing aging demographics coupled with the growing incidence of acute myeloid leukemia are the factors driving the growth of global acute myeloid leukemia biomarker testing market over the forecast period. It is reported by American Society of Clinical Oncology (ASCO) that acute myeloid leukemia is the second most common type of leukemia found in adults. Acute myeloid leukemia (AML) accounts for 32% of all leukemia cases that is an estimated 19,520 people of all age groups in the United States are likely to get diagnosed with acute myeloid leukemia. The leading market players are investing in R&D so as to develop innovative biomarker testing kits for acute myeloid leukemia (AML).
For instance, Abbott ‘s Vysis EGR1 FISH kit is widely used for detecting the LSI EGR1 probe target on a 5q chromosome in bone marrow patients also Abbott Real Time IDH1 is launched recently for diagnostics of acute myeloid leukemia (AML).
Due to this factor, the global acute myeloid leukemia (AML) biomarker testing market is expected to grow with significant CAGR during the forecast period. However, high cost for biomarker tests, stringent regulatory policies, and low detection rates are expected to hamper the acute myeloid leukemia (AML) biomarker testing market.
